Clinical trial · Interventional
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer
NCT01686958CI-TRIAL-00043348completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to evaluate that the magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MR-Guided Transurethral US Ablation of Prostate Tissue | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MR-Guided Transurethral US Ablation
- description
- MR-Guided Transurethral US Ablation of Prostate Tissue
- interventionNames
- Device: MR-Guided Transurethral US Ablation of Prostate Tissue
Primary outcomes (2)
- measure
- Safety - Evaluate the Frequency of Treatment Related Adverse Events
- timeFrame
- 12 months from the Treatment Date
- description
- All reported adverse events were recorded. The frequency was measured as the number of study participants who experienced a treatment/device related adverse event after receiving treatment delivery with PAD-105, the investigational device.
- measure
- Safety - Evaluate the Severity of Treatment Related Adverse Events
- timeFrame
- 12 months from the Treatment Date
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 65 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Male, age ≥65 * Patient with low-risk, early-stage organ-confined prostate cancer (Stage T1c or T2a, N0, M0). * Gleason score 6 (3+3) * Prostate-specific antigen (PSA) ≤ 10 ng/ml * Eligible for MR imaging (DOC-10252) * Meets the following criteria on pre-treatment transrectal ultrasound imaging: 1. No cysts or calcifications \> 1.0 cm in size 2. No evidence of extraprostatic extension or seminal vesicle invasion 3. Overall prostate size less than 5 cm in sagittal length and less than 7 cm in diameter * Biopsy confirmed adenocarcinoma of the prostate, performed at least 6 weeks prior to and no more than 6 months prior to the scheduled treatment. * Eligible for General Anesthesia, as defined in American Society of Anesthesiologists (ASA) * Normal rectal anatomy and rectal mucosa on digital rectal examination Exclusion Criteria: * Bleeding disorder * Abnormal coagulation and current anticoagulant therapy. * Acute or chronic Urinary Tract Infection * Interest in future fertility * History of allergy relevant medication or other * History of any other malignancy other than skin cancer * Patients with peripheral arterial disease with intermittent claudication or Leriches Syndrome * Prior treatment of the prostate gland * Prior treatment with 5 alpha reductase inhibitor allowed (not as prostate cancer treatment or prevention) as long as drug has been stopped for minimum 3 months * History of any major rectal or pelvic surgery * History of ulcerative colitis or other chronic inflammatory conditions affecting rectum * History of documented clinical prostatitis requiring therapy within previous 6 months * History of urethral and bladder outlet disorders, including urethral stricture disease, urethral diverticulae, bladder neck contracture, urethral fistulae which had required prior urethrotomy, urethral stenting, urethroplasty or chronic indwelling urethral catheter * Patients with artificial urinary sphincter or any penile implant (metallic or non-metallic) * Neurologic bladder disorders * Untreated bladder stones * History of acute urinary retention * Confirmed or suspected bladder cancer * Urinary sphincter abnormalities * Active untreated gross hematuria for any cause * Post Void Residual (PVR) bladder volume \> 250 mL * Obstructing median lobe enlarged out of proportion to the rest of the prostate and protruding significantly into the bladder Additional exclusion criteria on file....
References
Publications (1)
- DERIVEDChin JL, Billia M, Relle J, Roethke MC, Popeneciu IV, Kuru TH, Hatiboglu G, Mueller-Wolf MB, Motsch J, Romagnoli C, Kassam Z, Harle CC, Hafron J, Nandalur KR, Chronik BA, Burtnyk M, Schlemmer HP, Pahernik S. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. Eur Urol. 2016 Sep;70(3):447-55. doi: 10.1016/j.eururo.2015.12.029. Epub 2016 Jan 6. PMID 26777228